CN105124078A - 一种栀子花降糖降脂保健茶及其制备方法 - Google Patents
一种栀子花降糖降脂保健茶及其制备方法 Download PDFInfo
- Publication number
- CN105124078A CN105124078A CN201510656881.7A CN201510656881A CN105124078A CN 105124078 A CN105124078 A CN 105124078A CN 201510656881 A CN201510656881 A CN 201510656881A CN 105124078 A CN105124078 A CN 105124078A
- Authority
- CN
- China
- Prior art keywords
- parts
- gardenia
- blood
- component
- health protection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000111489 Gardenia augusta Species 0.000 title description 16
- 238000000034 method Methods 0.000 title description 15
- 244000269722 Thea sinensis Species 0.000 title 1
- 239000003814 drug Substances 0.000 claims description 58
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 45
- 230000036541 health Effects 0.000 claims description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 239000000284 extract Substances 0.000 claims description 36
- 241001122767 Theaceae Species 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 23
- 235000013399 edible fruits Nutrition 0.000 claims description 22
- 241000405414 Rehmannia Species 0.000 claims description 20
- 230000008901 benefit Effects 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 20
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 15
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 15
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 15
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 15
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 15
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 15
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 15
- 240000000171 Crataegus monogyna Species 0.000 claims description 15
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 15
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 15
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 15
- 239000009636 Huang Qi Substances 0.000 claims description 15
- 241000208688 Eucommia Species 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 14
- 244000179560 Prunella vulgaris Species 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 13
- 235000008113 selfheal Nutrition 0.000 claims description 13
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 12
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 12
- 241000830535 Ligustrum lucidum Species 0.000 claims description 12
- 235000008708 Morus alba Nutrition 0.000 claims description 12
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 11
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims description 11
- 235000003956 Luffa Nutrition 0.000 claims description 11
- 240000000249 Morus alba Species 0.000 claims description 11
- 240000005001 Paeonia suffruticosa Species 0.000 claims description 11
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 235000003373 curcuma longa Nutrition 0.000 claims description 11
- 235000013976 turmeric Nutrition 0.000 claims description 11
- 241000123844 Artemisia anomala Species 0.000 claims description 10
- 235000014290 Artemisia anomala Nutrition 0.000 claims description 10
- 241000132012 Atractylodes Species 0.000 claims description 10
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims description 10
- 244000050983 Luffa operculata Species 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 230000006837 decompression Effects 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000004064 recycling Methods 0.000 claims description 7
- 238000000967 suction filtration Methods 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 238000005057 refrigeration Methods 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 241000241413 Propolis Species 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims description 2
- 229940069949 propolis Drugs 0.000 claims description 2
- 241000157835 Gardenia Species 0.000 claims 22
- 244000163122 Curcuma domestica Species 0.000 claims 3
- 210000004369 blood Anatomy 0.000 description 95
- 239000008280 blood Substances 0.000 description 94
- 230000000694 effects Effects 0.000 description 57
- 240000001972 Gardenia jasminoides Species 0.000 description 51
- 206010012601 diabetes mellitus Diseases 0.000 description 32
- 208000002193 Pain Diseases 0.000 description 30
- 230000036407 pain Effects 0.000 description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 210000004185 liver Anatomy 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 230000001603 reducing effect Effects 0.000 description 20
- 210000004072 lung Anatomy 0.000 description 19
- 208000004880 Polyuria Diseases 0.000 description 16
- 230000035619 diuresis Effects 0.000 description 16
- 235000013616 tea Nutrition 0.000 description 15
- 206010037660 Pyrexia Diseases 0.000 description 13
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000003110 anti-inflammatory effect Effects 0.000 description 11
- 235000018958 Gardenia augusta Nutrition 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000007789 gas Substances 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- 231100000331 toxic Toxicity 0.000 description 10
- 230000002588 toxic effect Effects 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 9
- 208000031226 Hyperlipidaemia Diseases 0.000 description 9
- 206010023126 Jaundice Diseases 0.000 description 9
- 230000034994 death Effects 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 244000008991 Curcuma longa Species 0.000 description 8
- 206010020772 Hypertension Diseases 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- 208000026435 phlegm Diseases 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 208000001431 Psychomotor Agitation Diseases 0.000 description 7
- 206010038743 Restlessness Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 210000001015 abdomen Anatomy 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- MQBFFYQCZCKSBX-UHFFFAOYSA-N 5-hydroxy-6,7,8-trimethoxy-2-(3,4,5-trimethoxyphenyl)chromen-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2OC3=C(OC)C(OC)=C(OC)C(O)=C3C(=O)C=2)=C1 MQBFFYQCZCKSBX-UHFFFAOYSA-N 0.000 description 6
- 244000197580 Poria cocos Species 0.000 description 6
- 235000008599 Poria cocos Nutrition 0.000 description 6
- 229940007550 benzyl acetate Drugs 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 229930003935 flavonoid Natural products 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 6
- 235000017173 flavonoids Nutrition 0.000 description 6
- 230000023597 hemostasis Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000002398 materia medica Substances 0.000 description 6
- 238000010926 purge Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 206010000077 Abdominal mass Diseases 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 208000001780 epistaxis Diseases 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 201000005577 familial hyperlipidemia Diseases 0.000 description 5
- 229930182478 glucoside Natural products 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000004371 toothache Diseases 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 206010010741 Conjunctivitis Diseases 0.000 description 4
- 206010013935 Dysmenorrhoea Diseases 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 208000037093 Menstruation Disturbances Diseases 0.000 description 4
- 206010027339 Menstruation irregular Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 4
- 240000007164 Salvia officinalis Species 0.000 description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000019522 cellular metabolic process Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 229940096919 glycogen Drugs 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 208000006750 hematuria Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 206010022437 insomnia Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000005906 menstruation Effects 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 235000005412 red sage Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 229920001864 tannin Polymers 0.000 description 4
- 239000001648 tannin Substances 0.000 description 4
- 235000018553 tannin Nutrition 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 206010049865 Achromotrichia acquired Diseases 0.000 description 3
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 3
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 3
- 206010013954 Dysphoria Diseases 0.000 description 3
- 229930188400 Gardenin Natural products 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 240000008866 Ziziphus nummularia Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000008131 glucosides Chemical class 0.000 description 3
- 208000014617 hemorrhoid Diseases 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 231100000862 numbness Toxicity 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 208000008265 Favism Diseases 0.000 description 2
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 description 2
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 2
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 2
- 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 241000218231 Moraceae Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- VLCHQFXSBHIBRV-KNNWKXJLSA-N Mussaenosidic acid Natural products O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@@H]3[C@@H](O)[C@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@](O)(C)CC2 VLCHQFXSBHIBRV-KNNWKXJLSA-N 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- YSIFYNVXJOGADM-KDYWOABDSA-N Shanzhiside Chemical compound O([C@H]1[C@H]2[C@@H](C(=CO1)C(O)=O)[C@H](O)C[C@@]2(O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YSIFYNVXJOGADM-KDYWOABDSA-N 0.000 description 2
- PVPIPGMAEAJMTH-UHFFFAOYSA-N Shanzhiside Natural products OCC1OC(OC2OC=C(C3C(O)CC(O)C23)C(=O)O)C(O)C(O)C1O PVPIPGMAEAJMTH-UHFFFAOYSA-N 0.000 description 2
- 101000693619 Starmerella bombicola Lactone esterase Proteins 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- HLXRWTJXGMHOFN-XJSNKYLASA-N Verbenalin Chemical compound O([C@@H]1OC=C([C@H]2C(=O)C[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HLXRWTJXGMHOFN-XJSNKYLASA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000034526 bruise Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000023852 carbohydrate metabolic process Effects 0.000 description 2
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- -1 glucoside methyl esters Chemical class 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001114 myogenic effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 208000037921 secondary disease Diseases 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- JKBKMIKSUBLJRK-UHFFFAOYSA-N 2-propylsulfanylpyrimidine Chemical compound CCCSC1=NC=CC=N1 JKBKMIKSUBLJRK-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002368 Anger Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 229910001369 Brass Chemical class 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000759833 Cornus officinalis Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 241001065361 Gynostemma Species 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010018833 Haematocoele Diseases 0.000 description 1
- 208000005873 Hematocele Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000219138 Luffa Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- HLXRWTJXGMHOFN-UHFFFAOYSA-N Verbenalin Natural products C12C(C)CC(=O)C2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O HLXRWTJXGMHOFN-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000010951 brass Chemical class 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 229940124579 cold medicine Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000004920 hematocele of tunica vaginalis testis Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 230000008965 mitochondrial swelling Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000005982 spleen dysfunction Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000025301 tympanitis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 239000002918 waste heat Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种栀子花降糖降脂保健茶,所述栀子花降糖降脂保健茶中包括以下重量份数的原料:栀子花10~50份,生地10~20份,夏枯草10~20份,杜仲10~20份,当归10~20份,黄芪10~20份,三棱10~20份,绞股蓝10~20份,桑白皮10~20份,丝瓜络10~20份,山茱萸10~20份,郁金10~20份,刘寄奴10~20份,决明子10~20份,白术10~20份,山楂10~20份,丹皮10~20份,女贞子10~20份。现代医学研究,栀子花凉血排毒,能清理血液垃圾,促使体内细胞的新陈代谢;再加上一些活血化瘀,对脂肪和血清甘油三酯均有明显降低作用的中药材,这些药材大多口感清淡,不影响栀子花清雅幽香的味道,使人易于接受,更能较好的达到降脂降糖的功效。
Description
技术领域
本发明涉及含有来源于植物组份的降糖降脂保健品,特别涉及一种栀子花降糖降脂保健茶及其制备方法。
背景技术
随着工业化的发展,饮食结构的变化、生活条件的改善,超重和肥胖人群的数量在世界范围内迅速增长,并呈低龄化趋势,成为全球性严重影响健康的流行病,因此,寻找健康有效的降糖方法具有很现实的重要意义,安全有效的降糖活性物质一直是人们期待解决肥胖问题的关键。医学研究还表明,中药牛蒡子可以影响体内脂质代谢,可显著降低血清和肝脏中的胆固醇。具有降血脂、抗菌、降血糖、抗氧化作用,并能干扰机体对脂肪的吸收,促进摄入的脂肪排出体外。
降糖降脂方法很多,有饮食疗法、运动疗法、药物疗法及临床治疗等.这些方法或多或少都有不足之处,有的还易引起副作用,如腹泻、厌食等.而保健用品降糖具有使用方便,无毒副作用,功效显著等特点,而倍受消费者青睐。
现代城市生活的高速发展,也带来一系列富贵病。其中“三高”和肥胖是困扰人们的首要敌人。“三高症”是指高血压、高血糖(糖尿病)和高血脂症。通常伴随着肥胖。它们是现代社会所派生出来的“富贵病”,可能单独存在,也可能相互关联。如:糖尿病人很容易同时患上高血压或高血脂症,而高血脂又是动脉硬化形成和发展的主要因素,动脉硬化患者血管弹性差加剧血压升高,所以后期都形成了“三高症”。关于三高是什么有资料统计,在中国人的十大死亡原因中,与代谢疾病相关的死亡率就高达35.7%,与“三高”相关的死亡人数也占总死亡人数的27%。高血脂可以引起血管栓塞;高血压可以引起脑出血和脑血管破裂;高血糖可以引起糖尿病。世界卫生组织曾经明确提出,防止心血管病的第一道防线就是减少“三高”和控制“三高”。很多糖尿病人都伴有高脂血症,因此人们通常把糖尿病与高脂血症称为姐妹病,并认为高血脂是糖尿病的继发症。据统计大约40%的糖尿病病人有脂代谢紊乱。其特点是甘油三酯增高和高密度脂蛋白降低。糖尿病引起血脂增高的原因是由于糖尿病人胰岛素不足时,体内脂酶活泼性是减低的,因此容易血脂增高。另一方面糖尿病本身除糖代谢紊乱外同时还伴脂肪、蛋白质和水、电介质的紊乱。经常有游离脂肪酸从脂肪库中动员出来,使血中甘油三酯及游离脂肪酸浓度增高。再一方面2型糖尿病人进食过多,运动少,促使体内脂类合成增多,这也是造成血脂增高的原因。而肥胖伴高血脂者,由于胰岛素受体数相对减少,从而产生胰岛素抵抗,易诱发糖尿病。血脂增高者还易引起心、脑血管并发症。
栀子性苦、寒、无毒;气微,味微酸而苦;入心、肝、肺、胃经。栀子花含黄酮类栀子素、果胶、鞣质、藏红花素等,根、叶、花皆可入药,有镇静、降压,抑菌、致泻、镇痛、抗炎,调节平滑肌,加速软组织的愈合等作用,有泻火除烦,消炎祛热,清热利尿,凉血解毒之功效。
栀子花苦寒,能血分而清邪热,宽肠通便,防癌,栀子花含有纤维素,能预防痔疮的发作和直肠癌瘤的发生。栀子花根、叶、果实均可入药,有泻火除烦,消炎祛热、清热利尿,凉血解毒之功效。
栀子花、果实、叶和根可入药,一般泡茶或煎汤服。栀子含栀子甙、去羟栀子甙、鸡屎藤次甙甲酯及少量山栀甙,有清热利尿、凉血解毒、黄疸、血淋痛涩、目红肿痛、火毒疮、降血压等功效。其中栀子果入药,主治热病高烧,心烦不眠,实火牙痛,口舌生疮,鼻规,吐血,眼结膜炎,疮疡肿毒,黄疸型传染性肝炎,蚕豆病,尿血;外用治外伤出血、扭挫伤。根入药主治传染性肝炎,跌打损伤,风火牙痛。
《本草纲目》称其“悦颜色,《千金翼》面膏用之。”《滇南本草》称其“泻肺火,止肺热咳嗽,止鼻衄血,消痰。”性味归经:性寒,味甘苦;入肺、肝经。功效主治:清肺止咳,凉血止血。主治肺热咳嗽,鼻,咯痰,肿毒等病症。主要成分:栀子花含有三萜成分,栀子花酸A、B和子酸。含挥发油,包括乙酸苄酯、乙酸芳樟酯,另含色素甙、木蜜醇等。另外,还含有碳水化合物、蛋白质、粗纤维及多种维生素。
栀子花含乙酸苄酯、乙酸芳樟酯、乙酯苏合香酯等成分。用栀子花采用浸提法可生产栀子花浸膏浸膏得率0.1-0.13%可广泛用于化妆品香料和食品香料。采用水蒸气蒸馏法可生产栀子花油。得油率0.02%左右。栀子花油可配制多种花香型香水、香皂、化妆品香精。此外可用减压分馏方法将栀子花油的乙酸苄酯及乙酸芳樟酯单离出来作为日用化妆常用主香剂或协调剂也常用于食品如口香糖的香精。
现在各种降糖降脂保健品,药品泛滥,但大多数徒有其表,大张旗鼓的虚假宣传,很可能没有任何保健功能,但造成人身体的巨大伤害,因此,寻找健康有效的降糖方法具有很现实的重要意义。安全有效的降糖活性物质一直是人们期待解决肥胖问题的关键。中药降糖降脂,具有无毒、能被生物体完全吸收的优点,是我们研究的主要方向。现在市场迫切需要开发一种有降血脂、抗菌、降血糖、抗氧化作用,并能干扰机体对脂肪的吸收,促进摄入的脂肪排出体外的降糖降脂产品,并具有无毒、能被生物体完全吸收的保健品。
发明内容
本发明所要解决的技术问题在于,现在市场的大多数降糖产品鱼龙混杂,虚假宣传,很可能没有任何保健功能,但造成人身体的巨大伤害,因此,寻找健康有效的降糖方法具有很现实的重要意义,安全有效的降糖降脂活性物质一直是人们期待解决三高问题的关键。现代医学研究,栀子花凉血排毒,可降低血清总胆固醇及三酰甘油含量,促进体内细胞的增殖,强化和增强白血球,“血小板”,使T细胞以3倍的速度增长,强化免疫力,提升抗癌之功效;促使体内磷钙及维他命D在组合上之平衡,维持人体成长;能清理血液垃圾,促使体内细胞的新陈代谢;再加上一些活血化瘀,对脂肪和血清甘油三酯均有明显降低作用的中药材,且能改善微循环,这些药材大多口感清淡,不影响栀子花茶清淡幽香的味道,使人易于接受,更能较好的达到降脂降糖的功效。
为解决上述技术难题,本发明提供一种栀子花降糖降脂保健茶,其所述栀子花降糖降脂保健茶中包括以下重量份数的原料:栀子花10~50份,生地10~20份,夏枯草10~20份,杜仲10~20份,当归10~20份,黄芪10~20份,三棱10~20份,绞股蓝10~20份,桑白皮10~20份,丝瓜络10~20份,山茱萸10~20份,郁金10~20份,刘寄奴10~20份,决明子10~20份,白术10~20份,山楂10~20份,丹皮10~20份,女贞子10~20份。
所述栀子花降糖降脂保健茶,其所述栀子花降糖降脂保健茶中各种原料的重量份数可以为:栀子花10~40份,生地10~15份,夏枯草10~15份,杜仲10~15份,当归10~15份,黄芪10~15份,三棱10~15份,绞股蓝10~15份,桑白皮10~15份,丝瓜络10~20份,山茱萸10~20份,郁金10~20份,刘寄奴10~20份,决明子10~20份,白术10~20份,山楂10~20份,丹皮10~20份,女贞子10~20份。
所述栀子花降糖降脂保健茶,其所述栀子花降糖降脂保健茶中各种原料的重量份数还可以为:栀子花10~30份,生地10~20份,夏枯草10~20份,杜仲10~20份,当归10~20份,黄芪10~20份,三棱10~20份,绞股蓝10~20份,桑白皮10~20份,丝瓜络10~15份,山茱萸10~15份,郁金10~15份,刘寄奴10~15份,决明子10~15份,白术10~15份,山楂10~15份,丹皮10~15份,女贞子10~15份。
为解决上述技术问题,本发明还提供一种栀子花降糖降脂保健茶的制备方法,其所述栀子花降糖降脂保健茶的制备步骤包括以下方面:
a.栀子花的制备,成为组分1;
b.将其余原料提取的药液浓缩;成为组分2;
d.将组分1、组分2混合,浓缩制粒、杀菌消毒后装袋当茶饮。
所述步骤a中,可以取收获的栀子花洗净,晾晒时间在7-12小时即可,干透;将所述栀子花放入5-10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,将2次提取液合并静置,减压回收乙醇,并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分1。
所述步骤b中,可以将剩余原料洗净去杂,晾干,粉碎成颗粒,加水浸泡1小时;将浸泡好的原料置多功能提取罐中加水煎煮二次;第一次加总药材10倍量的水,煎煮1.5~2小时,取煎液,滤过;第二次加总量7倍量的水,煎煮1~1.2小时,取两次煎液混合,滤过,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分2。
所述步骤c中,可以将组分1与组分2合并,置入双效真空浓缩器中,浓缩至90℃时相对密度为1.25的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量,然后加糊精放入制粒机中制粒,紫外线灭菌,包装即得。
为解决上述技术问题,本发明再提供一种栀子花降糖降脂保健茶的制备方法,其制备步骤还可以为:
a.栀子花的制备,作为组分1;
b.将所述其余原料药加乙醇浸泡、提取3次作为组分2;
c.将组分1和组分2混合,浓缩后加适量蜂胶调和,紫外线消毒杀菌后装瓶。
所述步骤a中,可以将洗净晾晒的栀子花放于10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分1。
所述步骤b中,可以将所述其余原料放入5-10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,将2次提取液合并静置,减压回收乙醇,并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分2。
本发明清血排毒,滋阴补肾,能清理血液垃圾,促使体内细胞的新陈代谢;再加上一些活血化瘀,对脂肪和血清甘油三酯均有明显降低作用的中药材,且能改善微循环,这些药材大多口感清淡,不影响栀子花茶清香幽雅的味道,使人易于接受,更能较好的达到降脂降糖的功效。
具体实施方式
降糖降脂方法很多,有饮食疗法、运动疗法、药物疗法及临床治疗等.这些方法或多或少都有不足之处,有的还易引起副作用,如腹泻、厌食等.而保健用品降糖具有使用方便,无毒副作用,功效显著等特点,而倍受消费者青睐。
现代城市生活的高速发展,也带来一系列富贵病。其中“三高”和肥胖是困扰人们的首要敌人。“三高症”是指高血压、高血糖(糖尿病)和高血脂症。通常伴随着肥胖。它们是现代社会所派生出来的“富贵病”,可能单独存在,也可能相互关联。如:糖尿病人很容易同时患上高血压或高血脂症,而高血脂又是动脉硬化形成和发展的主要因素,动脉硬化患者血管弹性差加剧血压升高,所以后期都形成了“三高症”。关于三高是什么有资料统计,在中国人的十大死亡原因中,与代谢疾病相关的死亡率就高达35.7%,与“三高”相关的死亡人数也占总死亡人数的27%。高血脂可以引起血管栓塞;高血压可以引起脑出血和脑血管破裂;高血糖可以引起糖尿病。世界卫生组织曾经明确提出,防止心血管病的第一道防线就是减少“三高”和控制“三高”。很多糖尿病人都伴有高脂血症,因此人们通常把糖尿病与高脂血症称为姐妹病,并认为高血脂是糖尿病的继发症。据统计大约40%的糖尿病病人有脂代谢紊乱。其特点是甘油三酯增高和高密度脂蛋白降低。糖尿病引起血脂增高的原因是由于糖尿病人胰岛素不足时,体内脂酶活泼性是减低的,因此容易血脂增高。另一方面糖尿病本身除糖代谢紊乱外同时还伴脂肪、蛋白质和水、电介质的紊乱。经常有游离脂肪酸从脂肪库中动员出来,使血中甘油三酯及游离脂肪酸浓度增高。再一方面2型糖尿病人进食过多,运动少,促使体内脂类合成增多,这也是造成血脂增高的原因。而肥胖伴高血脂者,由于胰岛素受体数相对减少,从而产生胰岛素抵抗,易诱发糖尿病。血脂增高者还易引起心、脑血管并发症。
栀子性苦、寒、无毒;气微,味微酸而苦;入心、肝、肺、胃经。栀子花含黄酮类栀子素、果胶、鞣质、藏红花素等,根、叶、花皆可入药,有镇静、降压,抑菌、致泻、镇痛、抗炎,调节平滑肌,加速软组织的愈合等作用,有泻火除烦,消炎祛热,清热利尿,凉血解毒之功效。
栀子花苦寒,能血分而清邪热,宽肠通便,防癌,栀子花含有纤维素,能预防痔疮的发作和直肠癌瘤的发生。栀子花根、叶、果实均可入药,有泻火除烦,消炎祛热、清热利尿,凉血解毒之功效。
栀子花、果实、叶和根可入药,一般泡茶或煎汤服。栀子含栀子甙、去羟栀子甙、鸡屎藤次甙甲酯及少量山栀甙,有清热利尿、凉血解毒、黄疸、血淋痛涩、目红肿痛、火毒疮、降血压等功效。其中栀子果入药,主治热病高烧,心烦不眠,实火牙痛,口舌生疮,鼻规,吐血,眼结膜炎,疮疡肿毒,黄疸型传染性肝炎,蚕豆病,尿血;外用治外伤出血、扭挫伤。根入药主治传染性肝炎,跌打损伤,风火牙痛。
《本草纲目》称其“悦颜色,《千金翼》面膏用之。”《滇南本草》称其“泻肺火,止肺热咳嗽,止鼻衄血,消痰。”性味归经:性寒,味甘苦;入肺、肝经。功效主治:清肺止咳,凉血止血。主治肺热咳嗽,鼻,咯痰,肿毒等病症。主要成分:栀子花含有三萜成分,栀子花酸A、B和子酸。含挥发油,包括乙酸苄酯、乙酸芳樟酯,另含色素甙、木蜜醇等。另外,还含有碳水化合物、蛋白质、粗纤维及多种维生素。
栀子花含乙酸苄酯、乙酸芳樟酯、乙酯苏合香酯等成分。用栀子花采用浸提法可生产栀子花浸膏浸膏得率0.1-0.13%可广泛用于化妆品香料和食品香料。采用水蒸气蒸馏法可生产栀子花油。得油率0.02%左右。栀子花油可配制多种花香型香水、香皂、化妆品香精。此外可用减压分馏方法将栀子花油的乙酸苄酯及乙酸芳樟酯单离出来作为日用化妆常用主香剂或协调剂也常用于食品如口香糖的香精。
杜仲游离氨基酸极少,含有的少量蛋白质,是和绝大多数食品类似的完全蛋白,即能够水解检出对人体必需的8种氨基酸。测定了杜仲所含的15种矿物元素,其中有锌、铜、铁等微量元素,及钙、磷、钾、镁等宏量元素。药用杜仲,即为杜仲科植物杜仲的干燥树皮,是中国名贵滋补药材。其味甘,性温。有补益肝肾、强筋壮骨、调理冲任、固经安胎的功效。可治疗肾阳虚引起的腰腿痛或酸软无力,肝气虚引起的胞胎不固,阴囊湿痒等症。在《神农本草经》中被列为上品。现代研究杜仲具有清除体内垃圾,加强人体细胞物质代谢,防止肌肉骨骼老化,平衡人体血压,分解体内胆固醇,降低体内脂肪,恢复血管弹性,利尿清热,广谱抗菌,兴奋中枢神经,提高白血球药理作用。
生地:生地也叫生地黄,玄参科多年生草本植物地黄RehmanniaglutinosaLibosch.的新鲜或干燥的块根。清热、生津、润燥、滑肠、破瘀、生新、止痛、调经、金疮瘀、凉血、止血;鲜地黄和生地黄的作用是有所不同的。鲜地黄清热生津,可以止血和凉血,经常是用于热病伤阴,吐血、咽喉肿痛、舌绛烦渴、发斑发疹以及衄热等病症。相对于鲜地黄,生地黄是凉血清热,也可以生津,还可以养阴,多用于治疗阴虚内热、骨蒸劳热、舌绛烦渴、发斑发疹等问题。生地性寒,功能为滋阴补肾。不只生津止渴和凉血清热,还对血崩、月经不调、胎动不安、便秘等有作用,凡是血分有热伤阴的人,都可以经常服用。如果想要治疗温热病,可以用生地做清营汤;如果是治疗温病的后期,由于余热还没消尽,应该把生地用来煮青蒿鳖甲汤;另外,针对血热毒盛,斑疹紫黑,温热病严重热入营血的症状,可以服用生地制成的四生丸;一般要养阴生津来治疗内热消渴和便秘的,应该食用生地煮的曾液汤。
夏枯草为唇形科植物夏枯草PrunellavulgarisL.的干燥果穗。全国各地均产,主产于江苏、浙江、安徽、河南等地。夏季果穗呈棕红色时采收,除去杂质,晒干。生用。药性辛、苦,寒。归肝、胆经。功效清热泻火,明目,散结消肿。《神农本草经》:“主寒热、瘰疬、鼠瘘、头疮,破症。散瘿结气,脚肿湿痹。”《本草纲目》:“夏枯草治目疼,用砂糖水浸一夜用,取其能解内热,缓肝火也。楼全善云,夏枯草治目珠疼至夜则甚者,神效,或用苦寒药点之反甚者,亦神效。盖目珠连目本,肝系也,属厥阴之经。夜甚及点苦寒药反甚者,夜与寒亦阴故也。夏枯禀纯阳之气,补厥阴血脉,故治此如神,以阳治阴也。”
女贞子用于肝肾阴虚的目暗不明,视力减退,须发早白,腰酸耳鸣及阴虚发热等。本品能补肝肾阴,但药力平和,须缓慢取效。治目暗不明,常配熟地,郁金等同用,治须发早白,常配桑葚同用,阴虚发热,常配五味子。肝肾阴虚,头昏目眩、遗精耳鸣、腰膝酸软,须发早白,冠心病、高脂血症、高血压、慢性肝炎。对肝脏的保护作用研究认为,女贞子含有齐墩果酸,给大鼠皮下注射,可降低血清谷丙转氨酶,对四氯化碳诱发的肝损伤有明显保护作用,并能促进肝细胞再生.齐墩果酸亦可使肝内甘油三酯蓄积减少、肝细胞变性坏死明显减轻、糖原蓄积增加、血清γ球蛋白下降;超微结构可见肝细胞内线粒体肿胀与内质网囊泡变性减轻、肝组织间质炎症反应减弱。
三棱归肝、脾经。有破血行气,消积止痛的功效。用于症瘕痞块,痛经,瘀血经闭,胸痹心痛,食积胀痛。《本草纲目》:通肝经积血,女人月水,产后恶血。《开宝》:老癖症瘕,积聚结块,产后恶血血结,通月水,堕胎,止痛利气。
丝瓜络性凉,味甘。入肺、胃、肝经。通络,活血,祛风。用于痹痛拘挛、胸胁胀痛、乳汁不通。《本草便读》:丝瓜络,入经络,解邪热。热除则风去,络中津液不致结合而为痰,变成肿毒诸症,故云解毒耳。
山楂含多种维生素、山楂酸、酒石酸、柠檬酸、苹果酸等,还含有黄酮类、内酯、糖类、蛋白质、脂肪和钙、磷、铁等矿物质,所含的解脂酶能促进脂肪类食物的消化。促进胃液分泌和增加胃内酶素等功能。中医认为,山楂具有消积化滞、收敛止痢、活血化淤等功效。主治饮食积滞、胸膈痞满、疝气血淤闭经等症。山楂中含有山萜类及黄铜类等药物成分,具有显著的扩张血管及降压作用,有增强心肌、抗心律不齐、调节血脂及胆固醇含量的功能,山楂有活血化淤的功效,有助于解除局部淤血状态,对跌打损伤有辅助疗效;山楂所含的黄酮类和维生素C、胡萝卜素等物质能阻断并减少自由基的生成,能增强机体的免疫力,有防衰老、抗癌的作用;山楂中有平喘化痰、抑制细菌、治疗腹痛腹泻的成分。
丹皮,又名牡丹皮,中药名。为毛茛科植物牡丹干燥根皮。产于安徽、山东等地。秋季采挖根部,除去细根,剥取根皮,晒干。生用或炒用。《本草纲目》:“滋阴降火,解斑毒,利咽喉,通小便血滞。后人乃专以黄蘖治相火,不知丹皮之功更胜也。赤花者利,白花者补,人亦罕悟,宜分别之。”现代研究,所含牡丹酚及其以外的糖苷类成分均有抗炎作用;牡丹皮的甲醇提取物有抑制血小板作用;牡丹酚有镇静、降温、解热、镇痛、解痉等中枢抑制作用及抗动脉粥样硬化、利尿、抗溃疡等作用。
绞股蓝经现代医学研究发现,绞股蓝主要有效成分为多糖类、黄酮类、皂苷类及微量元素类,其功效主要是促进人体脂肪类物质代谢、营养人体细胞,同时具有不错的解毒消炎作用,广泛应用于高血脂、脂肪肝、肥胖、便秘、失眠、乙肝、慢性呼吸道炎症(咽喉炎、肠胃炎等)的治疗与保健。
茯苓味甘、淡、性平,入药具有利水渗湿、益脾和胃、宁心安神之功用。现代医学研究:茯苓能增强机体免疫功能,茯苓多糖有明显的抗肿瘤及保肝脏作用。茯苓性味甘淡平,入心、肺、脾经。具有渗湿利水,健脾和胃,宁心安神的功效。可治小便不利,水肿胀满,痰饮咳逆,呕逆,恶阻,泄泻,遗精,淋浊,惊悸,健忘等症。茯苓之利水,是通过健运脾肺功能而达到的,与其它直接利水的中药不同。用于脾虚泄泻,带下茯苓既能健脾,又能渗湿,对于脾虚运化失常所致泄泻、带下,应用茯苓有标本兼顾之效,常与党参、白术、山药等配伍。有可用为补肺脾,治气虚之辅佐药。
丹参苦,微寒。归心、肝经。祛瘀止痛,活血通经,清心除烦。用于月经不调,经闭痛经,症瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠。用于胸肋胁痛,风湿痹痛,症瘕结块,疮疡肿痛,跌仆伤痛,月经不调,经闭痛经,产后瘀痛等。治疗胸肋疼痛、症瘕结块,以及月经不调、经闭经痛具有良效。《纲目》载:丹参,按《妇人明理论》云,四物汤治妇人病,不问产前产后,经水多少,皆可通用,惟一味丹参散,主治与之相同。盖丹参能破宿血,补新血,安生胎,落死胎,止崩中滞下,调经脉。丹参主要成分丹参酮有扩张血管、改善循环、解除血管内凝血等作用,具有活血化痕之功效,并能促进肝脏血液循环,利于肝细胞再生。
郁金辛、苦,寒。归肝、心、肺经。功能主治行气化瘀,清心解郁,利胆退黄。用于经闭痛经,胸腹胀痛、刺痛,热病神昏,癫痫发狂,黄疸尿赤。行气解郁,凉血破瘀。治胸腹胁肋诸痛,失心癫狂,热病神昏,吐血,衄血,尿血,血淋,妇女倒经,黄疸。《药性论》载其:治女人宿血气心痛,冷气结聚,温醋摩服之。《唐本草》载其:主血积,下气,生肌,止血,破恶血,血淋,尿血,金疮。
黄芪具有补气固表、利水退肿、托毒排脓、生肌等功效。黄芪的药用迄今已有2000多年的历史,现代研究,黄芪含皂甙、蔗糖、多糖、多种氨基酸、叶酸及硒、锌、铜等多种微量元素。有增强机体免疫功能、保肝、利尿、抗衰老、抗应激、降压和较广泛的抗菌作用。但表实邪盛,气滞湿阻,食积停滞,痈疽初起或溃后热毒尚盛等实证。黄芪具有补气固表,利尿托毒,排脓,敛疮生肌的功效。用于气虚乏力,食少便溏,中气下陷,久泻脱肛,便血崩漏,表虚自汗,痈疽难溃,久溃不敛,血虚萎黄,内热消渴。《本经》记载:“主痈疽,久败疮,排脓止痛。补虚,小儿百病。”《日华子本草》记载:“助气壮筋骨,长肉补血。”
桑白皮为桑科植物桑MorusalbaL.的根皮。主产于安徽、河南、浙江、江苏、湖南等地。功效:泻肺平喘,利水消肿。用于肺热咳喘,面目浮肿,小便不利等症。《药性论》:使,平。能治肺气喘满,水气浮肿,主伤绝,利水道,消水气,虚劳客热头痛,内补不足。《日华子本草》:温,调中,下气。消痰止渴,利大小肠,开胃,下食,杀腹藏虫,止霍乱吐泻。
山茱萸,主治心下邪气寒热,温中,逐寒温痹,去三虫,久服轻身有强阴益精、安五脏、通九窍、止小便淋沥之功;久服明目、强力长年。山茱萸,又名山芋肉、药枣、实枣儿、枣皮、肉枣等,为我国常用名贵中药材,应用历史悠久。它以其补力平和、壮阳而不助火,滋阴而不腻膈,收敛而不留邪等特殊功效被历代医学所喜用。张仲景以山茱萸为君创制了“金匮肾气丸”。据化学分析,山茱萸含有生理活性较强的山茱萸甙、酒石酸、没食子酸、苹果酸、树酯、鞣质和多种维生素等有效成分,具有增强免疫、抗炎、抗菌等药理作用,是中医临床中常用的一味药。
刘寄奴它具有疗伤止血,破血通经,消食化积,醒脾开胃的功效。它可用于急性黄疸型肝炎,牙痛,慢性气管炎,口腔炎,咽喉炎,扁桃体炎,肾炎,疟疾;外用治眼结膜炎,中耳炎,疮疡,湿疹,外伤出血。破血通经,敛疮消肿。治经闭症瘕,胸腹胀痛,产后血瘀,跌打损伤,金疮出血,痈毒焮肿。《唐本草》:″主破血,下胀。″《日华子本草》:″治心腹痛,下气水胀、血气,通妇人经脉症结,止霍乱水泻。
决明子清热明目,润肠通便。用于目赤涩痛,羞明多泪,头痛眩晕,目暗不明,大便秘结。归肝、肾、大肠经。有减肥之功效。治风热赤眼,青盲,雀目,高血压,肝炎,肝硬化腹水,习惯性便秘。决明子花草茶的适宜症状和人群:决明子可以和其他花草茶搭配,具有不错的排毒排油腻功效。能达到功效:清热平肝、降脂降压、润肠通便、明目益睛。现代“电视族”、“电脑族”等易引起眼睛疲劳的人群不妨常喝,但夜晚最好少饮。
具体实施例1:
将晾晒好的栀子花泡入10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分1。
将其余原料药生地,夏枯草,杜仲,当归,黄芪,三棱,绞股蓝,桑白皮,丝瓜络,山茱萸,郁金,刘寄奴,决明子,白术,山楂,丹皮,女贞子。放入10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为80℃时1.06的浸膏,成为组分2。
将组分1和组分2合并后置入双效真空浓缩器中,浓缩至90℃时相对密度为1.36的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加糊精调和,制粒,紫外线消毒杀菌后装袋,冲服。
具体实施例2:
取收获的栀子花洗净,晾晒时间在7-12小时即可,干透;将所述栀子花5000g放入5-10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,将2次提取液合并静置,减压回收乙醇,并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分1。将剩余原料生地1500g,夏枯草1500g,杜仲1500g,当归1500g,黄芪1500g,三棱1500g,绞股蓝1500g,桑白皮1500g,丝瓜络1500g,山茱萸1500g,郁金1500g,刘寄奴1500g,决明子1500g,白术1500g,山楂1500g,丹皮1500g,女贞子1500g。洗净去杂,晾干,粉碎成颗粒,加水浸泡1小时;将浸泡好的原料置多功能提取罐中加水煎煮二次;第一次加总药材10倍量的水,煎煮1.5~2小时,取煎液,滤过;第二次加总量7倍量的水,煎煮1~1.2小时,取两次煎液混合,滤过,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分2。
;将过滤的滤液置入双效真空浓缩器中,浓缩至90℃时相对密度为1.05的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含1g生药量。然后制粒,装袋,紫外线灭菌,包装即得,使用时直接开水冲服。
具体实施例3:
取收获的栀子花洗净,晾晒时间在7-12小时即可,干透;将所述栀子花4500g放入5-10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,将2次提取液合并静置,减压回收乙醇,并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分1;将其他剩余原料生地1200g,夏枯草1100g,杜仲1200g,当归1200g,黄芪1100g,三棱1200g,绞股蓝1200g,桑白皮1100g,丝瓜络1200g,山茱萸1200g,郁金1200g,刘寄奴1300g,决明子1200g,白术1200g,山楂1200g,丹皮1200g,女贞子1100g,将其放入10倍量水中浸泡。投入多功能提取罐提取两次,第一次加8-10倍量水煎煮1-2小时,第二次加4-8倍量水煎煮1-2小时,合并两次煎液,过滤得滤液;加热浓缩至糊状,混合制备好的栀子花组分,制粒,紫外线杀菌消毒。使用时直接开水冲服。
药理学毒性试验
实验例1:本发明急性毒性试验
一、试验材料:动物:昆明种小鼠,体重18-25g,雌雄各半,山东大学生物试验室育种。药物:本发明(所有原材料混合煎煮2次,合并过滤,取药液)含0.0365mg/ml。
二、方法:
1、LD50计算:采用改良寇氏法,将小鼠随机分成5组,每组10只,雌雄各半,将本发明加蒸馏水溶解,配成最大浓度,按小鼠最大允许容量给药,所给剂量按生药量依次为18,14.4,11.5,9.2,7.4(g.kg-1),在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml,观察动物死亡情况。
2、最大耐受剂量测定(MTD值):取小鼠20只,雌雄各10只。将本发明加蒸馏水溶解,配成最高浓度,按动物的最大耐受量,以注射灌喂器能抽动为准。在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml(每ml含生药0.36g),总药量为18g生药/kg.d,相当临床成人50Kg体重用量的300倍。给药后连续观察7天。
三、试验结果:
在LD50计算中当用最大允许浓度和最大允许容量给予小鼠时(18g/Kg.d),未见小鼠死亡,即未测出LD50,只可求最大耐受剂量,在7天观察期中,动物其食欲、活动、毛色、精神状态等皆正常,发育正常,未见有死亡。即选用相当于临床剂量的300倍药量,并无不良反应发生,表明急性毒性极小,MTD>18g/Kg.d。
实验例2:急性毒性及长期毒性的试验结果
急性毒性试验:通过小白鼠一次性灌胃给予本发明,最高浓度35%,最大灌胃容量0.4ml/10g,剂量14g/kg(每g药粉相当于10g生药),连续观察7天,未发现任何毒性反应,因浓度和剂量无法增加,故未能测出该药的LD50。最大耐受量测定:以最高浓度,最大灌胃容量,小白鼠灌胃给药3次,间隔5小时,然后连续观察7天,无一例死亡。药粉剂量为>42g/kg.日(每g药粉相当于10g生药),按公斤体重计算相当于成人临床日用量的420倍。
长期毒性试验:为观察长期用药是否产生毒性反应,分别给予大鼠本发明饲服,按成人临床日用量的70倍和35倍(即7g/kg/日和3.5g/kg/日),连续给喂8周,未见大鼠的行为、进食、体重出现异常,与对照组比,血常规,肝肾功能,各种重要脏器均无异常改变,在所用药剂量范围内,未曾发现本发明的任何毒副反应。通过动物的急慢性毒性试验证实,本发明安全范围较大,是一种安全可靠的保健品。
药理学实验:
1材料和方法
1.1材料
1.1.1药物:本发明制备方法2制得的材料,煎煮,制备成含生药9g/10ml的试药,对照组:盐酸二甲双胍(上海华氏制药)。
1.1.2动物昆明种小鼠96只,雌雄各半,体重(20.5±2.3)g,均由青岛中医药大学动物实验中心提供。
1.1.3试剂和仪器:链脲佐菌素(STZ)(SERVER公司),购自华美公司。电子天平AB204-WO型(瑞士梅特勒-托有限公司);日立7150型全自动生化分析仪(日本)。
1.2方法
1.2.1造模与分组
糖尿病:动物购回,适应性喂养1周后,随机分为正常非糖尿病组8只和实验组40只,实验组于造模前禁食12小时,造模采用STZ55mg/kg一次性腹腔注射,给药后24小时测血糖、尿糖,连续3天,尿糖定性+++以上,血糖值超过16.5mmol/L,并持续不变者,确定为糖尿病形成。
将造模成功小鼠随机分为5组,模型对照组、二甲双胍组、本发明煎液高、中、低浓度组。
高脂血症:动物购回,适应性喂养1周后,随机分为正常非高脂血症组8只和实验组40只,实验组于造模前禁食12小时,造模给予1周以上含1%胆固醇,20%猪油、2%胆酸钠、1%丙基硫嘧啶的高脂乳剂,每天1次,连续7天。将造模成功小鼠随机分为5组,模型对照组、二甲双胍组、本发明煎液高、中、低浓度组。
1.2.2给药和测定方法正常对照组和模型对照组(ig等体积的生理盐水);盐酸二甲双胍组(ig,0.20g/kg);本发明煎液组(分别每天ig本发明煎液2.0g/kg,3.0g/kg,4.0g/kg)。各组分别灌胃给药,1次/d,连续30天。末次给药前12h禁食,给药后2h,摘眼取血,用全自动生化分析仪测定血糖和血脂。
1.2.3统计学处理所有数据用“-χ±S”表示,数据采用SPSS11.5统计软件分析处理,多组间比较若方差齐性用单向方差分析,若方差不齐用秩和检验,组内前后比较用配对t检验。
2结果
2.1降糖实验由表1可知,本发明煎液高、中、低浓度组均能显著降低高血糖小鼠模型的血糖,与模型对照组比较,差异有统计学意义(P<0.05)。
表1黄精煎液对小鼠血糖的影响(-χ±S)
注:与正常对照组比较,ΔΔP<0.01;与模型对照组比较,*P<0.05,**P<0.01;NS,生理盐水。
2.3降脂实验由表2可知,本发明煎液高、中、低浓度均能明显降低高血脂小鼠模型的TC、TG含量,与模型对照组比较,差异有统计学意义(P<0.05,P<0.01)。
表2黄精煎液对小鼠血脂的影响(-x±S)
注:与正常对照组比较,ΔΔP<0.01;与模型对照组比较,*P<0.05,**P<0.01;NS,生理盐水。
3讨论
近年来,随着人们生活水平的不断提高,糖尿病、冠心病等疾病发病率日益增加。中草药作用稳定,副作用少,研究具有降糖降脂作用的中草药,能为临床上治疗糖尿病、高脂血症提供更多的方法。现代药理研究表明,栀子性苦、寒、无毒;气微,味微酸而苦;入心、肝、肺、胃经。栀子花含黄酮类栀子素、果胶、鞣质、藏红花素等,根、叶、花皆可入药,有镇静、降压,抑菌、致泻、镇痛、抗炎,调节平滑肌,加速软组织的愈合等作用,有泻火除烦,消炎祛热,清热利尿,凉血解毒之功效。栀子花苦寒,能血分而清邪热,宽肠通便,防癌,栀子花含有纤维素,能预防痔疮的发作和直肠癌瘤的发生。栀子花根、叶、果实均可入药,有泻火除烦,消炎祛热、清热利尿,凉血解毒之功效。
本发明能够降低总胆固醇及三酰甘油含量,能清理血液垃圾,促使体内细胞的新陈代谢;再加上一些活血化瘀,对脂肪和血清甘油三酯均有明显降低作用的中药材,当归、黄芪味甘性平,归脾、肺、肾经,有益气养阴之效,《日华子本草》曰:“补五劳七伤......益脾胃,润心肺”。《本草纲目》云:“补诸虚......填精髓”。古人多用其治疗消渴病,相当于现代医学中的糖尿病。本实验为验证其降糖、降脂作用而设,结果发现其确有明显降糖、降脂作用。黄芪多糖,能降低肝细胞内的cAMP的含量从而阻碍磷酸化酶激活及糖原合成酶失活,导致糖原合成加速、糖原合成减慢,从而降低血糖;其降脂作用可能与黄芪多糖的抗氧化损伤、免疫调节、抑制炎性因子有关。综上所述,栀子花、当归、女贞子、黄芪等有良好的降糖降脂作用,临床上可用于治疗糖尿病和高脂血症。实验结果表明,本发明对小鼠体重、脂肪和血清甘油三酯均有明显降低作用,且能改善微循环,说明有降糖降血脂作用。
Claims (10)
1.一种栀子花降糖降脂保健茶,其特征在于,所述栀子花降糖降脂保健茶中包括以下重量份数的原料:栀子花10~50份,生地10~20份,夏枯草10~20份,杜仲10~20份,当归10~20份,黄芪10~20份,三棱10~20份,绞股蓝10~20份,桑白皮10~20份,丝瓜络10~20份,山茱萸10~20份,郁金10~20份,刘寄奴10~20份,决明子10~20份,白术10~20份,山楂10~20份,丹皮10~20份,女贞子10~20份。
2.根据权利要求1所述栀子花降糖降脂保健茶,其特征在于,所述栀子花降糖降脂保健茶中各种原料的重量份数为:栀子花10~40份,生地10~15份,夏枯草10~15份,杜仲10~15份,当归10~15份,黄芪10~15份,三棱10~15份,绞股蓝10~15份,桑白皮10~15份,丝瓜络10~20份,山茱萸10~20份,郁金10~20份,刘寄奴10~20份,决明子10~20份,白术10~20份,山楂10~20份,丹皮10~20份,女贞子10~20份。
3.根据权利要求1所述栀子花降糖降脂保健茶,其特征在于,所述栀子花降糖降脂保健茶中各种原料的重量份数为:栀子花10~30份,生地10~20份,夏枯草10~20份,杜仲10~20份,当归10~20份,黄芪10~20份,三棱10~20份,绞股蓝10~20份,桑白皮10~20份,丝瓜络10~15份,山茱萸10~15份,郁金10~15份,刘寄奴10~15份,决明子10~15份,白术10~15份,山楂10~15份,丹皮10~15份,女贞子10~15份。
4.一种如权利要求1~3项任一项所述栀子花降糖降脂保健茶的制备方法,其特征在于,所述栀子花降糖降脂保健茶的制备步骤包括以下方面:
a.栀子花的制备,成为组分1;
b.将其余原料提取的药液浓缩;成为组分2;
d.将组分1、组分2混合,浓缩制粒、杀菌消毒后装袋当茶饮。
5.根据权利要求4所述栀子花降糖降脂保健茶的制备方法,其特征在于,所述步骤a中,取收获的栀子花洗净,晾晒时间在7-12小时即可,干透;将所述栀子花放入5-10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,将2次提取液合并静置,减压回收乙醇,并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分1。
6.根据权利要求4所述栀子花降糖降脂保健茶的制备方法,其特征在于,所述步骤b中,将剩余原料洗净去杂,晾干,粉碎成颗粒,加水浸泡1小时;将浸泡好的原料置多功能提取罐中加水煎煮二次;第一次加总药材10倍量的水,煎煮1.5~2小时,取煎液,滤过;第二次加总量7倍量的水,煎煮1~1.2小时,取两次煎液混合,滤过,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分2。
7.根据权利要求4所述栀子花降糖降脂保健茶的制备方法,其特征在于,所述步骤c中,将组分1与组分2合并,置入双效真空浓缩器中,浓缩至90℃时相对密度为1.25的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量,然后加糊精放入制粒机中制粒,紫外线灭菌,包装即得。
8.一种如权利要求1~3中任一项所述栀子花降糖降脂保健茶的制备方法,其特征在于,其制备步骤还可以为:
a.栀子花的制备,作为组分1;
b.将所述其余原料药加乙醇浸泡、提取3次作为组分2;
c.将组分1和组分2混合,浓缩后加适量蜂胶调和,紫外线消毒杀菌后装瓶。
9.根据权利要求8所述栀子花降糖降脂保健茶的制备方法,其特征在于,所述步骤a中,将洗净晾晒的栀子花放于10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分1。
10.根据权利要求8所述栀子花降糖降脂保健茶的制备方法,其特征在于,所述步骤b中,将所述其余原料放入5-10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,将2次提取液合并静置,减压回收乙醇,并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分2。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510656881.7A CN105124078A (zh) | 2015-10-12 | 2015-10-12 | 一种栀子花降糖降脂保健茶及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510656881.7A CN105124078A (zh) | 2015-10-12 | 2015-10-12 | 一种栀子花降糖降脂保健茶及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105124078A true CN105124078A (zh) | 2015-12-09 |
Family
ID=54709960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510656881.7A Pending CN105124078A (zh) | 2015-10-12 | 2015-10-12 | 一种栀子花降糖降脂保健茶及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105124078A (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107173481A (zh) * | 2017-06-27 | 2017-09-19 | 黔西南州天麒绿色产业开发有限公司 | 一种降三高的保健茶及其制备方法 |
| CN113197907A (zh) * | 2021-06-21 | 2021-08-03 | 江西中医药大学 | 栀子花乙酸及其衍生物在制备用于治疗糖尿病的药物中的应用 |
| CN113397016A (zh) * | 2021-07-12 | 2021-09-17 | 陕西理工大学 | 一种用于降糖的山茱萸山楂佐餐茶的制备方法 |
| CN114041596A (zh) * | 2021-11-11 | 2022-02-15 | 肖国红 | 一种用于高血压病人降压治疗的食品组合物及其制备方法 |
| CN116898931A (zh) * | 2022-10-17 | 2023-10-20 | 创庭生物科技(上海)有限公司 | 一种具有辅助降低血液粘稠度的口服制剂 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103719495A (zh) * | 2013-12-31 | 2014-04-16 | 青岛恒波仪器有限公司 | 一种牛蒡子降糖降脂保健茶及其制备方法 |
| CN103749817A (zh) * | 2013-12-30 | 2014-04-30 | 南京博士牛生物科技有限公司 | 一种栀子茶及其制备方法 |
| CN104585405A (zh) * | 2013-11-03 | 2015-05-06 | 郑方 | 一种首乌花保健茶 |
-
2015
- 2015-10-12 CN CN201510656881.7A patent/CN105124078A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104585405A (zh) * | 2013-11-03 | 2015-05-06 | 郑方 | 一种首乌花保健茶 |
| CN103749817A (zh) * | 2013-12-30 | 2014-04-30 | 南京博士牛生物科技有限公司 | 一种栀子茶及其制备方法 |
| CN103719495A (zh) * | 2013-12-31 | 2014-04-16 | 青岛恒波仪器有限公司 | 一种牛蒡子降糖降脂保健茶及其制备方法 |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107173481A (zh) * | 2017-06-27 | 2017-09-19 | 黔西南州天麒绿色产业开发有限公司 | 一种降三高的保健茶及其制备方法 |
| CN113197907A (zh) * | 2021-06-21 | 2021-08-03 | 江西中医药大学 | 栀子花乙酸及其衍生物在制备用于治疗糖尿病的药物中的应用 |
| CN113397016A (zh) * | 2021-07-12 | 2021-09-17 | 陕西理工大学 | 一种用于降糖的山茱萸山楂佐餐茶的制备方法 |
| CN113397016B (zh) * | 2021-07-12 | 2022-08-02 | 陕西理工大学 | 一种用于降糖的山茱萸山楂佐餐茶的制备方法 |
| CN114041596A (zh) * | 2021-11-11 | 2022-02-15 | 肖国红 | 一种用于高血压病人降压治疗的食品组合物及其制备方法 |
| CN116898931A (zh) * | 2022-10-17 | 2023-10-20 | 创庭生物科技(上海)有限公司 | 一种具有辅助降低血液粘稠度的口服制剂 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102988638B (zh) | 一种青钱柳叶降脂降糖保健茶及其制备方法 | |
| CN104435775A (zh) | 一种中药保健酒及其制备方法 | |
| CN102784363B (zh) | 一种治疗胰腺癌的中药组合物及其制备方法 | |
| CN103749822B (zh) | 一种女贞子降压降脂保健茶及其制备方法 | |
| CN103734424B (zh) | 一种苦荞减肥降脂通便茶及其制备方法 | |
| CN104208302A (zh) | 一种降血脂的金樱子保健口服液及其制备方法 | |
| CN104904964A (zh) | 一种降糖降脂的罗布麻叶保健茶及其制备方法 | |
| CN105124078A (zh) | 一种栀子花降糖降脂保健茶及其制备方法 | |
| CN103301413A (zh) | 一种治疗高血脂合并高血糖症的中药组合物 | |
| CN103751707A (zh) | 一种牛蒡子美容祛斑的口服液及其制备方法 | |
| CN101607051B (zh) | 一种中药减肥组合物及其制备方法 | |
| CN103719495B (zh) | 一种牛蒡子降糖降脂保健茶及其制备方法 | |
| CN104365943A (zh) | 一种降糖降脂的槐角茶及其制备方法 | |
| CN104206594A (zh) | 一种降压降脂的桑寄生保健茶及其制备方法 | |
| CN103749824B (zh) | 一种绞股蓝降糖降压保健茶及其制备方法 | |
| CN104905267A (zh) | 一种决明子降血脂保健口服液及其制备方法 | |
| CN103749819B (zh) | 一种降糖降脂的山茱萸保健茶及其制备方法 | |
| CN105194421A (zh) | 一种夏枯草降血脂保健口服液及其制备方法 | |
| CN104206595A (zh) | 一种降脂降糖的地骨皮保健茶及其制备方法 | |
| CN104304602A (zh) | 一种软化血管的槐角茶及其制备方法 | |
| CN104306906A (zh) | 一种针对肥胖人群的荷叶减肥及其制备方法 | |
| CN105343593A (zh) | 一种降压降脂的夏枯草保健口服液及其制备方法 | |
| CN105494781A (zh) | 一种虎杖降糖降脂保健茶 | |
| CN105394282A (zh) | 一种可降压降糖降脂的葛根保健茶 | |
| CN105012873A (zh) | 一种降血脂的月见草保健口服液及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151209 |
|
| RJ01 | Rejection of invention patent application after publication |